Compare HWBK & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | BNTC |
|---|---|---|
| Founded | 1865 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.8M | 307.7M |
| IPO Year | 1996 | 2020 |
| Metric | HWBK | BNTC |
|---|---|---|
| Price | $39.49 | $8.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $23.29 |
| AVG Volume (30 Days) | 11.5K | ★ 179.4K |
| Earning Date | 11-10-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 31.42 | 6.67 |
| EPS | ★ 1.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.07 | $7.89 |
| 52 Week High | $40.60 | $16.31 |
| Indicator | HWBK | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 43.26 |
| Support Level | $37.10 | $8.26 |
| Resistance Level | $40.37 | $9.29 |
| Average True Range (ATR) | 0.71 | 0.58 |
| MACD | 0.15 | 0.14 |
| Stochastic Oscillator | 85.02 | 64.77 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, and checking, savings and money market accounts. It has two segments, banking and wealth management, with the banking segment earning the majority of its revenue and conducting general banking business, offering checking and savings accounts, internet banking, debit cards, certificates of deposit, brokerage services and others. Its primary source of revenue is net interest income derived from lending and deposit taking activities.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.